Breaking News Instant updates and real-time market news.

BIIB

Biogen

$296.08

-20.91 (-6.60%)

08:59
02/15/18
02/15
08:59
02/15/18
08:59

Morgan Stanley says Biogen Alzheimer trial change could be positive or negative

Morgan Stanley analyst Matthew Harrison noted that Biogen management indicated during an industry conference presentation that the enrollment for the Phase 3 aducanumab trials in Alzheimer's was being increased by 510 patients. Investors clearly took this as bad news, but "we just don't have enough information to know if the reason driving the change is bad or good," Harrison tells investors. The higher variability could be driven by a larger than expected treatment effect and "it is completely possible...aducanumab is actually doing better than expected," he added. Stating that the news doesn't fundamentally change his positive view on Biogen, Harrison maintains an Overweight rating on the shares.

  • 08

    Mar

  • 30

    May

BIIB Biogen
$296.08

-20.91 (-6.60%)

02/14/18
JEFF
02/14/18
NO CHANGE
Target $375
JEFF
Hold
Biogen swings back to Alzheimer's uncertainty, says Jefferies
At an industry conference today, Biogen provided some updates to its Phase III Alzheimer's study, including plans to add an additional 510 patients across the two aducanumab studies, Jefferies analyst Michael Yee tells investors in a research note. While these changes do not necessarily dramatically change the probability of success, it does change Wall Street's "sense of confidence," Yee contends. He believes the market will "swing back to uncertainty" on the Alzheimer's pendulum based on trial changes. Yee thinks Biogen needs to acquire de-risked "neuro/orphan companies" to "change the narrative" from being a binary Alzheimer's company to one with products even if Alzheimer's doesn't work. Yee keeps a Hold rating on Biogen shares with a $375 price target. The stock in afternoon trading is down 7% to $295.42.
02/15/18
PIPR
02/15/18
NO CHANGE
Target $407
PIPR
Overweight
Biogen selloff yesterday a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends using the selloff yesterday in shares of Biogen (BIIB) as a buying opportunity. The stock pulled back after management disclosed at a conference plans to up-size the Phase 3 aducanumab program by 510 patients total. While "this is a bit unnerving," particularly on the heels of another Phase 3 Alzheimer's failure for Merck's (MRK) verubecestat, the study remains blinded and variability on the primary endpoint can stem from a host of reasons, not all of them bad, Raymond tells investors in a research note titled "Aducanumab P3 Upsizing Doesn't Tell Us Much." The analyst does not think yesterday's news says much about the chances for an interim analysis or about aducanumab's efficacy profile. He keeps an Overweight rating on Biogen with a $407 price target.
02/15/18
ADAM
02/15/18
NO CHANGE
Target $350
ADAM
Hold
Biogen trial change does not alter efficacy assumptions, says Canaccord
Canaccord analyst Sumant Kulkarni noted Biogen announced an upsizing to its Alzheimer drug trial due to greater variability on the primary endpoint. The analyst said this was based on a pre-specified plan and does not change the efficacy assumptions of the drug. As a result he expects the shares to recover some of their losses. Kulkarni maintained his Hold rating and $350 price target on Biogen shares.
02/15/18
WBLR
02/15/18
NO CHANGE
WBLR
Outperform
Biogen enrollment increase is not unusual, says William Blair
William Blair analyst Matt Phipps believes increasing enrollment of Biogen's Phase III trials of aducanumab in prodromal Alzheimer's disease to ensure appropriate powering and confidence interval error margin, which caused yesterday's share selloff, is "prudent and not unusual." Based on his analysis, the trial is sufficiently powered to detect a benefit significantly below what was observed in the Phase Ib trial. The increase in variability in and of itself does not preclude trial success, Phipps tells investors in a research note. He sees "very limited" downside at current price levels if aducanumab were to fail, and adds that success of Biogen's growing earlier stage pipeline has the potential to provide additional upside. The analyst sees upside potential of over 50%, to $500 per share, if Phase III trials of aducanumab are successful, and a base support level slightly below $300 per share if the trials fail. Phipps keeps an Outperform rating on Biogen.

TODAY'S FREE FLY STORIES

PVG

Pretium Resources

$7.43

(0.00%)

18:11
12/14/18
12/14
18:11
12/14/18
18:11
Hot Stocks
Pretium Resources: Brucejack approved for production hike to 3,800 tonnes/day »

Pretium Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

17:52
12/14/18
12/14
17:52
12/14/18
17:52
Periodicals
FCA says four U.S. plants to have down-time in January, Detroit News says »

Fiat Chrysler said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

, CCNI

Command Center

$4.00

-0.075 (-1.84%)

17:43
12/14/18
12/14
17:43
12/14/18
17:43
Hot Stocks
Sonoma Pharmaceuticals CEO Jim Schutz resigns, Frederick Sandford succeeds »

Sonoma Pharmaceuticals…

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

CCNI

Command Center

$4.00

-0.075 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

, XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

17:38
12/14/18
12/14
17:38
12/14/18
17:38
General news
Week ending ETF scorecard: Energy, Financials lead the decline »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

IYR

DJ US Real Estate Index Fund

$80.37

-0.14 (-0.17%)

XLP

Consumer Staples Sector SPDR

$54.51

-0.97 (-1.75%)

XLY

Consumer Discretionary Sector SPDR

$102.33

-1.75 (-1.68%)

XLB

S&P Select Materials SPDR

$51.37

-0.37 (-0.72%)

XLF

Financial Select Sector

$24.25

-0.24 (-0.98%)

XLV

Health Care Select Sector SPDR

$88.99

-3.05 (-3.31%)

XLK

Technology Select Sector SPDR

$64.58

-1.6 (-2.42%)

XLI

Industrial Select Sector SPDR

$67.06

-0.95 (-1.40%)

GLD

SPDR Gold Shares

$117.10

-0.44 (-0.37%)

SLV

iShares Silver Trust

$13.69

-0.175 (-1.26%)

USO

United States Oil Fund

$10.83

-0.38 (-3.39%)

UNG

United States Natural Gas Fund

$30.78

-2.64 (-7.90%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.17

-0.365 (-0.44%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.72

-0.125 (-0.11%)

TLT

iShares 20+ Year Treasury Bond Fund

$118.47

0.38 (0.32%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.57

0.19 (0.19%)

SHY

iShares 1-3 Year Treasury Bond

$83.31

0.055 (0.07%)

IWD

iShares Russell 1000 Value

$116.15

-1.71 (-1.45%)

IWF

iShares Russell 1000 Growth

$135.70

-2.96 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEI

Ecology & Environment

$11.50

0.2 (1.77%)

17:35
12/14/18
12/14
17:35
12/14/18
17:35
Hot Stocks
Ecology & Environment receives Nasdaq noncompliance notice »

On December 13, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$8.96

-0.045 (-0.50%)

17:34
12/14/18
12/14
17:34
12/14/18
17:34
Hot Stocks
Luther Burbank announces systematic share repurchase plan »

Luther Burbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$1.33

0.01 (0.76%)

17:31
12/14/18
12/14
17:31
12/14/18
17:31
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLGT

Radiant Logistics

$4.76

-0.06 (-1.24%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on Radiant Logistics »

Radiant Logistics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$22.62

-1.39 (-5.79%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on KalVista »

KalVista files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

17:25
12/14/18
12/14
17:25
12/14/18
17:25
Hot Stocks
POTUS names Mick Mulvaney acting WH chief of staff »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$169.87

-2.585 (-1.50%)

17:20
12/14/18
12/14
17:20
12/14/18
17:20
Hot Stocks
Raytheon awarded $149.44M Navy contract for Standard Missile-2 Block IIIC »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$100.08

-2.73 (-2.66%)

17:15
12/14/18
12/14
17:15
12/14/18
17:15
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNCB

First National Community Bancorp, Inc.

$9.35

0.04 (0.43%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
First National Community Bancorp names R. Gregory Collins as new EVP »

FNCB Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.49

-0.48 (-0.96%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Textron awarded $314.29M Navy contract modification for LLTM procurement »

Textron has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Breaking Hot Stocks news story on Fluidigm »

Levin Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WTFC

Wintrust Financial

$67.41

-0.88 (-1.29%)

17:06
12/14/18
12/14
17:06
12/14/18
17:06
Hot Stocks
Wintrust Financial acquires Elektra Holding in roughly $51.9M deal »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$14.51

-0.35 (-2.36%)

17:04
12/14/18
12/14
17:04
12/14/18
17:04
Syndicate
Breaking Syndicate news story on AMC Entertainment »

AMC Entertainment files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.19

0.07 (0.07%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Equifax Canada acquires JLR Inc. »

Equifax Canada announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

DFS

Discover

$61.83

-1.41 (-2.23%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Discover executive chairman Nelms to step down effective December 31 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTO

AutoWeb

$2.34

-0.01 (-0.43%)

17:00
12/14/18
12/14
17:00
12/14/18
17:00
Hot Stocks
Daniel M. Negari reports 7.1% stake in AutoWeb »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.33

-1.39 (-1.77%)

16:46
12/14/18
12/14
16:46
12/14/18
16:46
Hot Stocks
Canadian National, Unifor Local 100 reach tentative agreement »

CN announced that a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.80

-1.66 (-3.50%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Recommendations
Cisco analyst commentary  »

Tigress Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 10

    Jan

  • 04

    Mar

TEL

TE Connectivity

$73.01

-0.59 (-0.80%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Hot Stocks
TE Connectivity raises quarterly dividend to 46c from 44c per share »

TE Connectivity board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$73.01

-0.59 (-0.80%)

16:42
12/14/18
12/14
16:42
12/14/18
16:42
Hot Stocks
TE Connectivity board approves $1.5B share repurchase authorization »

TE Connectivity announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRQS

Borqs Technologies

$3.85

0.1 (2.67%)

16:36
12/14/18
12/14
16:36
12/14/18
16:36
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.